| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/04/2005 | WO2005069994A2 Folate conjugates and complexes |
| 08/04/2005 | WO2005069966A2 Vascular grafts with amphiphilic block copolymer coatings |
| 08/04/2005 | WO2005054303A3 Cyclodextrin dimers and derivatives thereof, methods for preparing them and their use, in particular, for solubilizing pharmacologically active substances |
| 08/04/2005 | WO2005051305A3 Enhanced drug delivery |
| 08/04/2005 | WO2005048930A3 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 08/04/2005 | WO2005041936A3 Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material |
| 08/04/2005 | WO2005023175A3 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 08/04/2005 | WO2005010481A3 Preparation and use of gold glyconanoparticles |
| 08/04/2005 | WO2005007129A3 Topical formulations with bioactive components |
| 08/04/2005 | WO2005002516A3 Leukocyte internalized peptide-drug conjugates |
| 08/04/2005 | WO2004110498A3 Drug conjugate composition |
| 08/04/2005 | WO2004108072A3 Delivery of immune response modifier compounds using metal-containing particulate support materials |
| 08/04/2005 | WO2004093807A3 Somatostatin vectors |
| 08/04/2005 | WO2004089283A3 Compositions and methods for treating viral infections |
| 08/04/2005 | WO2004083234A3 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| 08/04/2005 | WO2004046309A3 Methods for inhibiting viral replication in vivo |
| 08/04/2005 | WO2003062198A3 Integrin targeted imaging agents |
| 08/04/2005 | US20050171342 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 08/04/2005 | US20050171328 hydrolytically unsatable linkages including estes, acetals, imines, peptides, protiens, oligonucleotides near the reactive end of polymer provide for a sufficient ciculation period for drug-polymer conjugate, hydrolytically breakdown the conjugate to release bound drug; slowing rate of kidney clearance |
| 08/04/2005 | US20050171232 Storing soft lens in aqueous solution containing methyl cellulose |
| 08/04/2005 | US20050171203 includes water, at least one preservative, at least one taste-masking agent, and an optional viscosity control agent; suitable for oral administration |
| 08/04/2005 | US20050171193 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 08/04/2005 | US20050171177 Method of treatment of Candida isolates |
| 08/04/2005 | US20050171127 Epzicom; coated tablet formulated with Ceolus" microcrystalline cellulose for once daily administration; synergistic HIV treatment |
| 08/04/2005 | US20050171083 Modified release pharmaceutical formulation |
| 08/04/2005 | US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II |
| 08/04/2005 | US20050171057 Pantoprazole cyclodextrin inclusion complexes |
| 08/04/2005 | US20050171047 Immunostimulatory nucleic acid molecules |
| 08/04/2005 | US20050171040 Chemically synthesized double stranded molecules; hypercholesterolemia, hyperlipidemia, cardiovascular and cerebrovascular disorders, aortic stenosis, peripheral vascular disease, atherosclerosis |
| 08/04/2005 | US20050171021 Buffered drug formulations for transdermal |
| 08/04/2005 | US20050171019 Administering an exendin modified with a polymer such as polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes |
| 08/04/2005 | US20050171014 ligand, a linker, and a cytotoxic agent, in which the linker is FALA; cell-targeted cancer therapy |
| 08/04/2005 | US20050171009 by addition of surfactants such as nonionic surfactants of the (poly)ethoxylated fatty acid type; storage stability to hydrophobic aggregation nuclei for several months under temperature stress |
| 08/04/2005 | US20050171001 Hemostatic compositions and devices |
| 08/04/2005 | US20050170509 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| 08/04/2005 | US20050170508 For transfecting nucleic acids in vivo or ex vivo; vesicle forming lipid and hydrophilic polymer; gene therapy |
| 08/04/2005 | US20050170436 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen |
| 08/04/2005 | US20050170404 Modified human growth hormone polypeptides and their uses |
| 08/04/2005 | US20050170392 OAT3 transporters expressed in blood brain barrier cells |
| 08/04/2005 | US20050170390 MCT1 transporters expressed in blood brain barrier cells |
| 08/04/2005 | US20050170371 Alopecia, acne, polycystic ovary disease, prostitic hypertrophy, and prostate cancer |
| 08/04/2005 | US20050170368 Tumor-associated antigenic target polypeptides for use as tools in treatment of cell proliferative disorders; antitumor and/or antiproliferative agents |
| 08/04/2005 | US20050170355 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases |
| 08/04/2005 | US20050170021 Drink containing ultrafine powder of ginseng and the method thereof |
| 08/04/2005 | US20050170012 Porous beta-tricalcium phosphate granules for regeneration of bone tissue |
| 08/04/2005 | US20050170007 Ude of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix |
| 08/04/2005 | US20050170004 electrostatically attaching the peptide, polysaccharide, or a glycoprotein to a nanoparticle (organic wax) prior to the oral ingestion, to inhibit enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein upon oral ingestion |
| 08/04/2005 | US20050169999 beta -carotene was dissolved in n-isobutyl or isobutyl acetate, hot solvent phase was dispersed in a modified water starch solution, evaporation of solvent, drying the dispersion; obtained beta -carotene used as colorant, for food, beverages, nutrition fortified food and pharmaceuticals |
| 08/04/2005 | US20050169997 Loading water insoluble drugs ( Nelfinavir, midazolam or indomethacin) or nicotine as water soluble drug onto ion exchange acrylic resins using water or a water miscible or water-immiscible solvent; efficient, environmentally friendly (less cosolvent); changes in release rate of drugs, taste masking |
| 08/04/2005 | US20050169996 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| 08/04/2005 | US20050169993 Sustained-release formulation |
| 08/04/2005 | US20050169990 dry mixing oxycodon (opioids) with trimethylammoniumethyl methacrylate chloride, forming tablet by granulation and compression, curing the dosage form; superior to those of uncured tablets |
| 08/04/2005 | US20050169988 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
| 08/04/2005 | US20050169986 Fast disintegrating tablets |
| 08/04/2005 | US20050169984 Preservation stability of drugs such as the penem antibiotic faropenem or faropenem daloxate by filling the capsule with an inorganic substance such as magnesium aluminometasilicate |
| 08/04/2005 | US20050169983 Chewable soft capsule |
| 08/04/2005 | US20050169982 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability |
| 08/04/2005 | US20050169981 Lactose monohydrate as diluent; tablets or capsules; stability is superior than either anhydrous lactose or starch as diluent |
| 08/04/2005 | US20050169976 Insulin administration apparatus |
| 08/04/2005 | US20050169971 Pellet or tablet attractive to livestock masking a drug such as benazepril; animal feed substrate, intimately mixed with coated particles of a carrier material and an active ingredient casing that is coated by a masking protective layer |
| 08/04/2005 | US20050169968 Conjugates comprising a biodegradable polymer and uses therefor |
| 08/04/2005 | US20050169941 Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines |
| 08/04/2005 | US20050169937 Attacking immune tolerant species; having at least one consensus amino acid sequence |
| 08/04/2005 | US20050169932 Uses of monoclonal antibody 8h9 |
| 08/04/2005 | US20050169930 PSCA: prostate stem cell antigen and uses thereof |
| 08/04/2005 | US20050169904 biodrug fusion protein comprising active mitochondrial protein or peptide, a mitochondrial membrane-permeant peptide and linking to a mitochondrial targeting sequence; targeting sequence is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm; mitochondrial disorders |
| 08/04/2005 | US20050169902 Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
| 08/04/2005 | US20050169899 Exploiting endogenous import and export mechanisms of ribonucleic acid trafficking which utilize nuclear targeting peptides containing nonclassical nuclear localization signals |
| 08/04/2005 | US20050169886 Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds |
| 08/04/2005 | US20050169883 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| 08/04/2005 | US20050169881 O(chloracetyl-carbamoyl) fumagillol -470 conjugated to hydroxypropyl(meth)acrylamide-methacrylic acid copolymer results in a water soluble composition, lowers the neurotoxicity of TNP-470, avoids penetration of TNP-470 to the cerebrospinal fluid |
| 08/04/2005 | US20050169834 Method for producing alpha-alumina formed body |
| 08/04/2005 | CA2593571A1 Methods and compositions for facilitating metabolic control |
| 08/04/2005 | CA2554587A1 Medicinal soap |
| 08/04/2005 | CA2554188A1 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
| 08/04/2005 | CA2554075A1 Method of protecting sensitive molecules from a photopolymerizing environment |
| 08/04/2005 | CA2553714A1 Support accumulating in injured part in vascular channel |
| 08/04/2005 | CA2553647A1 Articles comprising magnetic material and bioactive agents |
| 08/04/2005 | CA2553426A1 Liposome composition for delivery of therapeutic agents |
| 08/04/2005 | CA2553254A1 Long-term delivery formulations and methods of use thereof |
| 08/04/2005 | CA2553221A1 Folate conjugates and complexes |
| 08/04/2005 | CA2552584A1 Pyrimidyl phosphonate antiviral compounds and methods of use |
| 08/04/2005 | CA2552328A1 Non-animal origin stabilizers and processes for producing the same |
| 08/04/2005 | CA2552043A1 Transglutaminase mediated conjugation of peptides |
| 08/04/2005 | CA2551807A1 Lipid-based dispersions useful for drug delivery |
| 08/04/2005 | CA2495839A1 Anti-photoaging cosmeceutical composition |
| 08/03/2005 | EP1559725A1 Antigen recognizing antibody |
| 08/03/2005 | EP1559438A1 Hemostatic compositions and devices |
| 08/03/2005 | EP1559431A1 Pharmaceutical composition for thrombin peptide derivatives |
| 08/03/2005 | EP1558763A2 Identification of diet-regulated disease-associated genes |
| 08/03/2005 | EP1558630A2 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use |
| 08/03/2005 | EP1558562A1 Cationic cardiolipin analogs and use thereof |
| 08/03/2005 | EP1558551A2 Calixarene-based guest-host assemblies for guest storage and transfer |
| 08/03/2005 | EP1558290A2 Heat pasteurized liquids containing glucosamine |
| 08/03/2005 | EP1558273A2 Treatment and prevention of pulmonary conditions |
| 08/03/2005 | EP1558241A2 Pharmaceutical compositions and methods of using taxane derivatives |
| 08/03/2005 | EP1558228A1 Topical administration of basic antifungal compositions to treat fungal infections of the nails |
| 08/03/2005 | EP1558227A1 Injectable 2,6-diisopropylphenol-containing anesthetic composition and methods |
| 08/03/2005 | EP1558226A2 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 08/03/2005 | EP1558225A1 Adhesive composition for dermal patch and production process thereof |